drugset / Trial / NCT01290211

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

NCT01290211

Phase 1 Completed 28 enrolled ViiV Healthcare Pfizer · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is will be an open-label, fixed-sequence, multiple dose crossover study in 2 cohorts of 14 healthy male and/or female subjects, to estimate the effect of maraviroc on the pharmacokinetics of amprenavir and ritonavir and fosamprenavir/ritonavir on the pharmacokinetics of maraviroc.

Timeline

Start
2011-04
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosamprenavir Small molecule 700 mg
Subject Fosamprenavir Small molecule 1400 mg
Subject Maraviroc Other / unclassified 300 mg
Subject Ritonavir Other / unclassified 100 mg

Indications

No indication recorded.